Scarica l'app Stockscreener
29.60
2.21%
-0.67
Pre-mercato:
30.00
0.40
+1.35%
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
Price-Driven Insight from (RAPP) for Rule-Based Strategy - news.stocktradersdaily.com
Wall Street Zen Upgrades Rapport Therapeutics (NASDAQ:RAPP) to Hold - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 5.4%Here's Why - MarketBeat
Rapport Therapeutics Shapes Focused Clinical Neuroscience Programs - Kalkine Media
HC Wainwright Issues Optimistic Forecast for RAPP Earnings - Defense World
FY2027 Earnings Forecast for RAPP Issued By HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
H.C. Wainwright raises Rapport Therapeutics stock price target to $40 on strong seizure drug data - Investing.com Canada
Rapport Therapeutics (NASDAQ:RAPP) Receives “Buy” Rating from BTIG Research - Defense World
Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know - sharewise.com
Rapport Therapeutics (NASDAQ:RAPP) Earns Buy Rating from BTIG Research - MarketBeat
BTIG Reiterates Rapport Therapeutics (RAPP) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics (RAPP) Valuation Check After a 60% Year-to-Date Share Price Surge - Yahoo Finance
RAP-219 Phase 2a Seizure Data and Planned Pivotal Trials Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Yahoo Finance
Affinity Asset Advisors LLC Purchases Shares of 199,643 Rapport Therapeutics, Inc. $RAPP - Defense World
Wall Street Zen Downgrades Rapport Therapeutics (NASDAQ:RAPP) to Sell - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Downgraded to Sell Rating by Wall Street Zen - Defense World
Rapport Therapeutics Announces Positive Phase 2a Post-Hoc Analysis of RAP-219 Demonstrating Early Efficacy in Drug-Resistant Focal Onset Seizures - Quiver Quantitative
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures - The Manila Times
Rapport Therapeutics Announces New Data and Post Hoc - GlobeNewswire
Rapport Therapeutics (RAPP) Valuation After Key Phase 2a Epilepsy Data Presentation Announcement - Sahm
Will Rapport Therapeutics Inc. stock see PE expansionJuly 2025 Momentum & Low Drawdown Momentum Trade Ideas - Newser
Is Rapport Therapeutics Inc. stock trading at a premium valuationWeekly Market Report & Weekly High Conviction Trade Ideas - Newser
(RAPP) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Rapport Therapeutics (RAPP) Stock Analysis Report | Financials & Insights - Benzinga
Rapport Therapeutics COO Cheryl Gault Sells 5,000 Shares - TradingView
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? - sharewise.com
Rapport Therapeutics (RAPP) Is Down 11.3% After Positive Phase 2a Data and $269M Offering – Has the Bull Case Changed? - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Shares Up 6.1%Here's What Happened - MarketBeat
A Look at Rapport Therapeutics’s Valuation as New RAP-219 Phase 2a Data Presentation Approaches - Sahm
How does Rapport Therapeutics Inc (RAPP) change from a tortoise to a hare? - Setenews
Could RAP-219’s Upcoming Data Reveal a Turning Point for Rapport Therapeutics’ Pipeline Strategy (RAPP)? - simplywall.st
Rapport Therapeutics to Present New Phase 2a Data Analysis - GlobeNewswire
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting - Yahoo Finance
What Analyst Ratings Reveal About Sagar Systech Limiteds Future ValueStock Buy Signals & Fast Growing Trading Plans - earlytimes.in
(RAPP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Can Rapport Therapeutics Inc. stock outperform in 2025 bull marketStop Loss & Long-Term Growth Stock Strategies - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at BTIG Research - MarketBeat
Can trapped investors hope for a rebound in Rapport Therapeutics Inc. - newser.com
What institutional flow reveals about Rapport Therapeutics Inc.Weekly Stock Analysis & Daily Entry Point Trade Alerts - newser.com
Will Rapport Therapeutics Inc. stock pay special dividendsJuly 2025 Reactions & Breakout Confirmation Trade Signals - newser.com
This Extreme Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Analyzing Rapport Therapeutics Inc. with risk reward ratio chartsTreasury Yields & Safe Capital Growth Tips - newser.com
BTIG Research Initiates Coverage on Rapport Therapeutics With Buy Rating, $47 Price Target - MarketScreener
BTIG Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - Nasdaq
What candlestick patterns are forming on Rapport Therapeutics Inc.Gap Up & Verified Entry Point Signals - newser.com
Why Rapport Therapeutics Inc. stock is a value investor pick2025 Technical Overview & Technical Pattern Based Signals - newser.com
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):